# US 2023/0398229 A1 · Antibody drug conjugates comprising sting agonists, combinations and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0398229 A1
- Document ID: US20230398229A1
- Status: Published application
- Kind: A1
- Application number: 18/179,699
- Filed: 2023-03-07
- Published: 2023-12-14
- Earliest claimed: 2022-03-07
- Applicants: Mersana Therapeutics, Inc.
- Inventors: Raghida A. BUKHALID; Naniye Cetinbas; Marc I. Damelin; Timothy B. Lowinger; Dorin Toader
- Web page: https://patentgrep.com/patent/US20230398229A1

## CPC

- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- C07K 16/11: Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/32: against translation products of oncogenes
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure provides combinations comprising HER2-targeted STING agonist antibody-drug conjugates and HER2-targeted therapies or immunotherapies. The present disclosure also provides uses of the combinations in treatment, e.g., treatment of cancer.

## Claims

### Claim 1

A combination therapy comprising at least one HER2-targeted STING agonist antibody-drug conjugate and at least one HER2-targeted therapy or at least one immunotherapy, wherein the HER2-targeted STING agonist antibody-drug conjugate is a conjugate of Formula (A):
wherein the conjugate comprises a HER2 antibody comprising a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence FTFSSYSMN (SEQ ID NO: 5); a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence YISSSSSTIYYADSVKG (SEQ ID NO: 6); a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence GGHGYFDL (SEQ ID NO: 7); and a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence RASQSVSSSYLA (SEQ ID NO: 12); a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence GASSRAT (SEQ ID NO: 13); and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence QQYHHSPLT (SEQ ID NO: 14), and d15 is about 8.

### Claim 2 (depends on 1)

The conjugate of claim 1, wherein the HER2 antibody specifically binds to an epitope of the human HER2 receptor that includes residues 452 to 531 of the extracellular domain of the human HER2 receptor, residues 474 to 553 of SEQ ID NO: 1 or residues 452 to 531 of SEQ ID NO: 16.

### Claim 3 (depends on 1)

The combination of claim 1, comprising at least one HER2-targeted STING agonist antibody-drug conjugate and at least one HER2-targeted therapy.

### Claim 4 (depends on 1)

The combination of claim 1, comprising at least one HER2-targeted STING agonist antibody-drug conjugate and at least one immunotherapy.

### Claim 5 (depends on 1)

The combination of claim 1, wherein the HER2-targeted STING agonist antibody-drug conjugate enhances the efficacy of the HER2-targeted therapy or the immunotherapy.

### Claim 6 (depends on 3)

The combination of claim 3, wherein the HER2-targeted therapy is an antibody or antigen binding fragment thereof that specifically binds HER2, a HER2-targeted antibody-drug conjugate that specifically binds HER2 or a small molecule inhibitor of HER2.

### Claim 7 (depends on 6)

The combination of claims 6, wherein the antibody or antigen binding fragment thereof that specifically binds HER2 is a HER2 antibody, a HER2 dimerization inhibitor antibody or a combination thereof.

### Claim 8 (depends on 7)

The combination of claim 7, wherein the HER2 antibody or the HER2 dimerization inhibitor antibody is trastuzumab, pertuzumab or margetuximab or biosimilars thereof.

### Claim 9 (depends on 6)

The combination of claim 6, wherein HER2-targeted therapy is trastuzumab, pertuzumab, a combination of trastuzumab and pertuzumab, margetuximab, a biosimilar of trastuzumab, a biosimilar of pertuzumab, a combination of a biosimilar of trastuzumab and a biosimilar of pertuzumab, or a biosimilar of margetuximab.

### Claim 10 (depends on 1)

The combination of claim 1, comprising at least one HER2-targeted STING agonist antibody-drug conjugate and trastuzumab, pertuzumab, a combination of trastuzumab and pertuzumab, margetuximab, a biosimilar of trastuzumab, a biosimilar of pertuzumab, a combination of a biosimilar of trastuzumab and a biosimilar of pertuzumab or a biosimilar of margetuximab.

### Claim 11 (depends on 6)

The combination of claim 6, wherein the HER2-targeted antibody-drug conjugate that specifically binds HER2 is ado-trastuzumab emtansine (T-DM1) or famtrastuzumab deruxtecan (trastuzumab deruxtecan).

### Claim 12 (depends on 1)

The combination of claim 1, comprising at least one HER2-targeted STING agonist antibody-drug conjugate and ado-trastuzumab emtansine (T-DM1) or fam-trastuzumab deruxtecan (trastuzumab deruxtecan).

### Claim 13 (depends on 6)

The combination of claim 6, where the small molecule inhibitor of HER2 is tucatinib, neratinib or lapatinib.

### Claim 14 (depends on 1)

The combination of claim 1, comprising at least one HER2-targeted STING agonist antibody-drug conjugate and tucatinib, neratinib or lapatinib.

### Claim 15 (depends on 4)

The combination of claim 4, wherein the immunotherapy is an immune checkpoint inhibitor.

### Claim 16 (depends on 15)

The combination of claim 15, wherein the immune checkpoint inhibitor is a monoclonal antibody, a humanized antibody, a fully human antibody, a fusion protein or a combination thereof.

### Claim 17 (depends on 15)

The combination of claim 15, wherein the immune checkpoint inhibitor is a PD-1 inhibitor or a PD-L1 inhibitor.

### Claim 18 (depends on 17)

The combination of claim 17, wherein the PD-1 inhibitor or the PD-L1 inhibitor is avelumab, durvalumab, dostarlimab, pembrolizumab, cemiplimab, nivolumab, or atezolizumab.

### Claim 19 (depends on 1)

The combination of claim 1, comprising at least one HER2-targeted STING agonist antibody-drug conjugate and avelumab, durvalumab, dostarlimab, pembrolizumab, cemiplimab, nivolumab, or atezolizumab.

### Claim 20 (depends on 1)

A method for treating, preventing, delaying the progression of or otherwise ameliorating a symptom of a cancer in a subject comprising administering the combination of claim 1.

### Claim 21 (depends on 20)

The method of claim 20, wherein the cancer is anal cancer, astrocytoma, leukemia, lymphoma, head and neck cancer, liver cancer, testicular cancer, cervical cancer, sarcoma, hemangioma, esophageal cancer, eye cancer, laryngeal cancer, mouth cancer, mesothelioma, skin cancer, myeloma, oral cancer, rectal cancer, colorectal cancer, throat cancer, bladder cancer, breast cancer, urothelial cancer, uterine cancer, ovarian cancer, prostate cancer, lung cancer, non-small cell lung cancer (NSCLC), colon cancer, pancreatic cancer, renal cancer, gastric cancer or gastric esophagogastric junction cancer.

### Claim 22 (depends on 21)

The method of claim 21, wherein the cancer is breast cancer, gastric cancer, gastric esophagogastric junction cancer, colorectal cancer or non-small cell lung cancer.

### Claim 23 (depends on 20)

The method of claim 20, wherein the immune checkpoint inhibitor and the conjugate are administered simultaneously.

### Claim 24 (depends on 20)

The method of claim 20, wherein the HER2-targeted STING agonist antibody-drug conjugate and the HER2-targeted therapy or the immunotherapy are administered simultaneously.

### Claim 25 (depends on 20)

The method of claim 20, wherein the HER2-targeted STING agonist antibody-drug conjugate and the HER2-targeted therapy or the immunotherapy are administered sequentially in either order or in alternation.

### Claim 26 (depends on 20)

The method of claim 20, wherein the HER2-targeted STING agonist antibody-drug conjugate is administered prior to the HER2-targeted therapy or the immunotherapy.

### Claim 27 (depends on 20)

The method of claim 20, wherein the HER2-targeted STING agonist antibody-drug conjugate is administered after the HER2-targeted therapy or the immunotherapy.

### Claim 28 (depends on 1)

The combination of claim 1, wherein the HER2-targeted STING agonist antibody-drug conjugate and the HER2-targeted therapy or the immunotherapy are formulated in the same formulation.

### Claim 29 (depends on 1)

The combination of claim 1, wherein the HER2-targeted STING agonist antibody-drug conjugate and the HER2-targeted therapy or the immunotherapy are formulated in separate formulations.

### Claim 30 (depends on 1)

A kit comprising the combination of claim 1 and an instruction for administration.
